Amylin receptor agonist: difference between revisions
Diff·revision 17 → 18·21:36, 25 Jun 2025
Difference between revision 17 and revision 18 of Amylin receptor agonist. 7 lines changed; the page grew by 1,038 bytes.
| Revision 17 — 07:48, 6 Jun 2025 DrTitration (talk) the half-life in the lead was the terminal figure; label it as such 3,927 bytes +18 | Revision 18 — 21:36, 25 Jun 2025 IcodecIndra (talk) split §Pharmacology into receptor binding and downstream signalling 4,965 bytes +1,038 | ||
|---|---|---|---|
| 27 | The gastrointestinal adverse-effect profile resembles that of the incretin agonists, with nausea predominating and concentrated during escalation. Whether combining two agents that both delay gastric emptying compounds this is a question the combination trials address only indirectly. | 27 | The gastrointestinal adverse-effect profile resembles that of the incretin agonists, with nausea predominating and concentrated during escalation. Whether combining two agents that both delay gastric emptying compounds this is a question the combination trials address only indirectly. |
| 28 | 28 | ||
| + | 29 | == Analytical notes == | |
| + | 30 | Amylin analogues are among the more demanding peptides to characterise, precisely because of the property they were engineered to remove. Residual aggregation propensity means that size-exclusion chromatography and, where available, orthogonal light-scattering methods carry more weight in a specification than they would for a non-aggregating peptide.{{r|usp1503,ich_q6b}} | |
| + | 31 | ||
| + | 32 | The distinction between reversible self-association and irreversible aggregation matters here as it does for acylated peptides: a size-based method run under dissociating conditions can report a clean profile on material that shows high-molecular-weight species under native conditions. See [[Peptide aggregation]]. | |
| + | 33 | ||
| 29 | == References == | 34 | == References == |
| 30 | {{reflist}} | 35 | {{reflist}} |
| 31 | <ref name="hay2015">Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." ''Pharmacological Reviews'' 67(3):564–600 (2015). PMID 26071095.</ref> | 36 | <ref name="hay2015">Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." ''Pharmacological Reviews'' 67(3):564–600 (2015). PMID 26071095.</ref> |
| 32 | <ref name="lau2021">Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled trial." ''The Lancet'' 398(10317):2160–2172 (2021). PMID 34798060.</ref> | 37 | <ref name="lau2021">Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled trial." ''The Lancet'' 398(10317):2160–2172 (2021). PMID 34798060.</ref> |
| + | 38 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| + | 39 | <ref name="ich_q6b">International Council for Harmonisation, ''Q6B: Specifications — Test Procedures and Acceptance Criteria for Biotechnological/Biological Products'' (1999).</ref> | |
| 33 | 40 | ||
| 34 | == See also == | 41 | == See also == |